- Home
- SNTG vs GNPX Comparison
SNTG vs GNPX Comparison
Compare SNTG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | GNPX |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.4M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SNTG | GNPX |
|---|---|---|
| Price | $2.17 | $2.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.3K | ★ 1.6M |
| Earning Date | 12-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,507.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $1.71 |
| 52 Week High | $12.70 | $55.00 |
Technical Indicators
Market Signals| Indicator | SNTG | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 45.10 |
| Support Level | $2.22 | $2.20 |
| Resistance Level | $2.45 | $3.11 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 40.00 | 13.29 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.